Is Inhibrx Stock a Good Investment?
Inhibrx Investment Advice | INBX |
- Examine Inhibrx's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Inhibrx's leadership team and their track record. Good management can help Inhibrx navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Inhibrx's business and its evolving consumer preferences.
- Compare Inhibrx's performance and market position to its competitors. Analyze how Inhibrx is positioned in terms of product offerings, innovation, and market share.
- Check if Inhibrx pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Inhibrx's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Inhibrx stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Inhibrx is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Inhibrx Stock
Researching Inhibrx's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 24.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.14. Some equities with similar Price to Book (P/B) outperform the market in the long run. Inhibrx recorded earning per share (EPS) of 119.39. The entity had not issued any dividends in recent years.
To determine if Inhibrx is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Inhibrx's research are outlined below:
| Inhibrx had very high historical volatility over the last 90 days | |
| Inhibrx has high likelihood to experience some financial distress in the next 2 years | |
| Inhibrx was previously known as INXB Old and was traded on NASDAQ Exchange under the symbol INXB. | |
| The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M). | |
| Inhibrx currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52. | |
| Inhibrx has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Kayyem Jon Faiz of 34843 shares of Inhibrx at 14.2269 subject to Rule 16b-3 |
Inhibrx Quarterly Liabilities And Stockholders Equity |
|
Inhibrx uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Inhibrx. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Inhibrx's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Inhibrx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Inhibrx's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-12 | 2020-12-31 | -0.54 | -0.47 | 0.07 | 12 | ||
2021-05-13 | 2021-03-31 | -0.59 | -0.51 | 0.08 | 13 | ||
2023-03-06 | 2022-12-31 | -0.79 | -0.95 | -0.16 | 20 | ||
2020-11-13 | 2020-09-30 | -0.6 | -0.77 | -0.17 | 28 | ||
2022-08-08 | 2022-06-30 | -0.78 | -0.97 | -0.19 | 24 | ||
2022-05-09 | 2022-03-31 | -0.6 | -0.8 | -0.2 | 33 | ||
2023-05-08 | 2023-03-31 | -0.84 | -1.12 | -0.28 | 33 | ||
2024-05-09 | 2024-03-31 | -1.04 | -1.44 | -0.4 | 38 |
Know Inhibrx's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inhibrx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inhibrx backward and forwards among themselves. Inhibrx's institutional investor refers to the entity that pools money to purchase Inhibrx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Manufacturers Life Insurance Co | 2024-06-30 | 0.0 | Metlife Inc | 2024-06-30 | 0.0 | Hhg Plc | 2024-06-30 | 0.0 | Simplex Trading, Llc | 2024-06-30 | 0.0 | State Of Wisconsin Investment Board | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Profund Advisors Llc | 2024-06-30 | 0.0 | Yakira Capital Management, Inc. | 2024-06-30 | 0.0 | Cnh Partners, Llc | 2024-06-30 | 0.0 | Dekabank Deutsche Girozentrale | 2024-06-30 | 26.4 K | Advisor Group Holdings, Inc. | 2024-06-30 | 6.7 K |
Inhibrx's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 203.82 M.Market Cap |
|
Inhibrx's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (5.55) | (5.27) |
Determining Inhibrx's profitability involves analyzing its financial statements and using various financial metrics to determine if Inhibrx is a good buy. For example, gross profit margin measures Inhibrx's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Inhibrx's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Inhibrx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inhibrx. Check Inhibrx's Beneish M Score to see the likelihood of Inhibrx's management manipulating its earnings.
Evaluate Inhibrx's management efficiency
Inhibrx has return on total asset (ROA) of (0.5746) % which means that it has lost $0.5746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.3105) %, meaning that it created substantial loss on money invested by shareholders. Inhibrx's management efficiency ratios could be used to measure how well Inhibrx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.82 in 2024. Return On Capital Employed is likely to drop to -0.91 in 2024. At this time, Inhibrx's Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 310.1 M in 2024, whereas Other Current Assets are likely to drop slightly above 24.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.92 | 0.97 | |
| Tangible Book Value Per Share | 0.92 | 0.97 | |
| Enterprise Value Over EBITDA | (8.34) | (8.75) | |
| Price Book Value Ratio | 41.17 | 43.23 | |
| Enterprise Value Multiple | (8.34) | (8.75) | |
| Price Fair Value | 41.17 | 43.23 | |
| Enterprise Value | 705.9 M | 614.9 M |
Inhibrx's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 2.877 |
Basic technical analysis of Inhibrx Stock
As of the 26th of November, Inhibrx retains the Downside Deviation of 2.86, market risk adjusted performance of 0.301, and Risk Adjusted Performance of 0.0585. Inhibrx technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Inhibrx's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibrx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibrx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inhibrx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inhibrx's Outstanding Corporate Bonds
Inhibrx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Inhibrx uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Inhibrx bonds can be classified according to their maturity, which is the date when Inhibrx has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Understand Inhibrx's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Inhibrx's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0585 | |||
| Market Risk Adjusted Performance | 0.301 | |||
| Mean Deviation | 2.32 | |||
| Semi Deviation | 2.7 | |||
| Downside Deviation | 2.86 | |||
| Coefficient Of Variation | 1501.04 | |||
| Standard Deviation | 3.21 | |||
| Variance | 10.33 | |||
| Information Ratio | 0.0266 | |||
| Jensen Alpha | 0.1209 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.0299 | |||
| Treynor Ratio | 0.291 | |||
| Maximum Drawdown | 16.8 | |||
| Value At Risk | (6.11) | |||
| Potential Upside | 5.54 | |||
| Downside Variance | 8.19 | |||
| Semi Variance | 7.29 | |||
| Expected Short fall | (2.85) | |||
| Skewness | 0.3306 | |||
| Kurtosis | 1.28 |
| Risk Adjusted Performance | 0.0585 | |||
| Market Risk Adjusted Performance | 0.301 | |||
| Mean Deviation | 2.32 | |||
| Semi Deviation | 2.7 | |||
| Downside Deviation | 2.86 | |||
| Coefficient Of Variation | 1501.04 | |||
| Standard Deviation | 3.21 | |||
| Variance | 10.33 | |||
| Information Ratio | 0.0266 | |||
| Jensen Alpha | 0.1209 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.0299 | |||
| Treynor Ratio | 0.291 | |||
| Maximum Drawdown | 16.8 | |||
| Value At Risk | (6.11) | |||
| Potential Upside | 5.54 | |||
| Downside Variance | 8.19 | |||
| Semi Variance | 7.29 | |||
| Expected Short fall | (2.85) | |||
| Skewness | 0.3306 | |||
| Kurtosis | 1.28 |
Consider Inhibrx's intraday indicators
Inhibrx intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Inhibrx stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Inhibrx Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of August 2024 Other Reports | ViewVerify |
Inhibrx Stock media impact
Far too much social signal, news, headlines, and media speculation about Inhibrx that are available to investors today. That information is available publicly through Inhibrx media outlets and privately through word of mouth or via Inhibrx internal channels. However, regardless of the origin, that massive amount of Inhibrx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Inhibrx news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Inhibrx relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Inhibrx's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Inhibrx alpha.
Inhibrx Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Inhibrx can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Inhibrx Corporate Management
| Leah JD | Corporate VP | Profile | |
| Mark Lappe | Chairman, Founder | Profile | |
| Charbel PharmD | Vice Planning | Profile | |
| BS CPA | Chief Officer | Profile | |
| Jeffrey Jensen | Executive Officer | Profile | |
| Brendan Eckelman | Executive Officer | Profile | |
| Carlos Bais | Executive Sciences | Profile |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.